Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation
文献类型：期刊论文
| 作者 | Zhang, Jingjing1,2,3; Ding, Lili1,2,3; Wang, Baocan1,2,3; Ren, Gaiyan1,2,3; Sun, Aning1,2,3; Deng, Chao1,2,3; Wei, Xiaohui1,2,3; Mani, Sridhar1,2,3; Wang, Zhengtao1,3,4; Dou, Wei1,3,4 |
| 刊名 | The Journal of pharmacology and experimental therapeutics
 |
| 出版日期 | 2015-02 |
| 卷号 | 352期号:2页码:315-24 |
| ISSN号 | 1521-0103 |
| DOI | 10.1124/jpet.114.218750 |
| 文献子类 | Article |
| 英文摘要 | Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium-induced colitis in mice by decreasing the activity of myeloperoxidase, the production of cytokines, the expression of proinflammatory genes, and the phosphorylation of IκB kinase, IκBα, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and the colon. Ligand pocket-filling mutant (S247W/C284W or S247W/C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-κB (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by small interfering RNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid-induced colitis in mice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/266581]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Wang, Zhengtao; Dou, Wei |
| 作者单位 | 1.Shanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C.D., X.W., Z.W., W.D.); 2.and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.); 3.Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); 4.and Departments of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York (S.M.) |
| 推荐引用方式 GB/T 7714 | Zhang, Jingjing,Ding, Lili,Wang, Baocan,et al. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation[J]. The Journal of pharmacology and experimental therapeutics,2015,352(2):315-24. |
| APA | Zhang, Jingjing.,Ding, Lili.,Wang, Baocan.,Ren, Gaiyan.,Sun, Aning.,...&Dou, Wei.(2015).Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation.The Journal of pharmacology and experimental therapeutics,352(2),315-24. |
| MLA | Zhang, Jingjing,et al."Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation".The Journal of pharmacology and experimental therapeutics 352.2(2015):315-24. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。